Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUNG BAJAJ

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1598177255
CMS profile
863830
Location
TUCSON, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$6,063.80

146 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,914.34 135
Consulting Fee $2,600.00 3
Education $549.46 8

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $1,384.98 9
E.R. Squibb & Sons, L.L.C. $944.89 4
BeiGene USA, Inc. $676.98 3
Mirati Therapeutics, Inc. $235.89 7
Novartis Pharmaceuticals Corporation $219.30 12
AstraZeneca Pharmaceuticals LP $208.06 6
GENZYME CORPORATION $172.16 7
Celgene Corporation $171.64 11
Merck Sharp & Dohme LLC $158.70 5
Genentech USA, Inc. $146.16 6
PFIZER INC. $133.07 8
Seagen Inc. $127.68 6
Apellis Pharmaceuticals, Inc. $123.39 2
SOBI, INC $95.00 1
Sumitomo Pharma America, Inc. $87.54 4
AVEO Pharmaceuticals, Inc. $84.50 1
Takeda Pharmaceuticals U.S.A., Inc. $81.83 4
SANOFI-AVENTIS U.S. LLC $69.99 1
AbbVie Inc. $56.64 3
CTI BioPharma Corp. $53.12 2
Lilly USA, LLC $47.64 3
Daiichi Sankyo Inc. $45.19 2
Eisai Inc. $44.42 2
Stemline Therapeutics Inc. $43.29 2
Blueprint Medicines Corporation $39.55 2
Incyte Corporation $38.00 2
Alexion Pharmaceuticals, Inc. $37.74 2
Kite Pharma, Inc. $37.02 2
Sun Pharmaceutical Industries Inc. $36.32 2
Gilead Sciences, Inc. $36.04 2
Regeneron Healthcare Solutions, Inc. $35.79 2
Exelixis Inc. $34.26 2
Bayer Healthcare Pharmaceuticals Inc. $33.12 2
JAZZ PHARMACEUTICALS INC. $30.76 1
Amgen Inc. $29.67 2
Boehringer Ingelheim Pharmaceuticals, Inc. $26.08 1
ARRAY BIOPHARMA INC $25.95 2
Alnylam Pharmaceuticals Inc. $24.80 1
Genmab U.S., Inc. $24.37 1
Kyowa Kirin, Inc. $20.57 1
TAIHO ONCOLOGY, INC. $20.31 1
Pharmacyclics LLC, An AbbVie Company $20.15 1
Puma Biotechnology, Inc. $19.51 1
EMD Serono, Inc. $18.05 1
Verity Pharmaceuticals Inc. $17.78 1
MorphoSys, US Inc. $17.48 1
GlaxoSmithKline, LLC. $16.37 1
Rigel Pharmaceuticals, Inc. $12.05 1

Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUNG BAJAJ

NPI 1598177255 · CMS profile ID 863830

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TUCSON, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598177255?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUNG BAJAJ, NPI 1598177255, CMS profile ID 863830. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598177255?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AUNG BAJAJ, NPI 1598177255, CMS profile ID 863830. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598177255?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AUNG BAJAJ, NPI 1598177255, CMS profile ID 863830, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1598177255?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

146 matching records · $6,063.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 146 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 146.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SOBI, INC $95.0008/30/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038126493 CMS
CTI BioPharma Corp. $26.6808/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039688345 CMS
Novartis Pharmaceuticals Corporation $23.8908/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991690651 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.7508/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055340825 CMS
Celgene Corporation $13.6908/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015072219 CMS
Novartis Pharmaceuticals Corporation $16.6008/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991690659 CMS
GENZYME CORPORATION $23.0108/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050276767 CMS
Janssen Biotech, Inc. $23.0408/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988173881 CMS
Incyte Corporation $17.0708/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044771417 CMS
Merck Sharp & Dohme LLC $10.3108/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048570749 CMS
Amgen Inc. $14.0908/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019823471 CMS
Novartis Pharmaceuticals Corporation $10.9908/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991690647 CMS
GENZYME CORPORATION $22.3307/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050276731 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.0007/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000502367 CMS
Celgene Corporation $30.4007/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015072111 CMS
Mirati Therapeutics, Inc. $13.1307/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057986005 CMS
Seagen Inc. $19.8207/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995822039 CMS
Genentech USA, Inc. $21.0907/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040307967 CMS
E.R. Squibb & Sons, L.L.C. $11.4007/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015072149 CMS
Kite Pharma, Inc. $15.2407/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025267207 CMS
PFIZER INC. $17.4007/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050335331 CMS
Janssen Biotech, Inc. $24.0307/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988173909 CMS
Celgene Corporation $10.0407/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015072088 CMS
Alexion Pharmaceuticals, Inc. $20.1107/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017066183 CMS
Apellis Pharmaceuticals, Inc. $52.2407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056332653 CMS
Puma Biotechnology, Inc. $19.5107/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059058919 CMS
Celgene Corporation $14.1407/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015072101 CMS
AstraZeneca Pharmaceuticals LP $24.0407/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014163861 CMS
Regeneron Healthcare Solutions, Inc. $14.3706/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999085187 CMS
Novartis Pharmaceuticals Corporation $5.5706/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991690643 CMS
Genentech USA, Inc. $32.1906/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040307975 CMS
Alexion Pharmaceuticals, Inc. $17.6306/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017039713 CMS
Seagen Inc. $6.4206/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995821991 CMS
Blueprint Medicines Corporation $20.1306/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051268349 CMS
SANOFI-AVENTIS U.S. LLC $69.9906/12/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050276701 CMS
Genentech USA, Inc. $28.0706/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040307963 CMS
GENZYME CORPORATION $23.6506/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050276697 CMS
Pharmacyclics LLC, An AbbVie Company $20.1506/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998281591 CMS
Genentech USA, Inc. $20.0305/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040307943 CMS
Novartis Pharmaceuticals Corporation $17.3605/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991690639 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.0305/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055340821 CMS
AVEO Pharmaceuticals, Inc. $84.5005/17/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049056511 CMS
Janssen Biotech, Inc. $150.0005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988173929 CMS
Alnylam Pharmaceuticals Inc. $24.8005/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006196523 CMS
Eisai Inc. $20.3305/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023303021 CMS
Mirati Therapeutics, Inc. $125.0005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057986001 CMS
Lilly USA, LLC $21.2305/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031279025 CMS
Seagen Inc. $8.9805/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995821941 CMS
Seagen Inc. $57.9905/08/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995822001 CMS
Stemline Therapeutics Inc. $17.4605/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040021837 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,443.52 57
PY2020 $210.53 10
PY2021 $223.70 5
PY2022 $2,383.78 53
PY2023 $6,063.80 146
PY2024 $4,389.93 153
PY2025 $1,929.21 77

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $69,315.45 13
PY2024 Principal investigator $159,082.35 13
PY2023 Principal investigator $164,364.70 19
PY2022 Principal investigator $100,228.85 8
PY2021 Principal investigator $11,909.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

13 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Exelixis Inc. $2,200.00 12/26/2025 Non-covered Recipient Entity
TMC HEALTHCARE
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385842
Principal investigator 1 Exelixis Inc. $2,200.00 12/01/2025 Non-covered Recipient Entity
TMC HEALTHCARE
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385844
Principal investigator 1 Exelixis Inc. $1,244.10 11/24/2025 Non-covered Recipient Entity
TMC HEALTHCARE
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385836
Principal investigator 1 Exelixis Inc. $8,967.00 11/04/2025 Non-covered Recipient Entity
TMC HEALTHCARE
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385838
Principal investigator 1 Exelixis Inc. $4,145.00 11/04/2025 Non-covered Recipient Entity
TMC HEALTHCARE
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385840
Principal investigator 1 Exelixis Inc. $7,275.00 10/29/2025 Non-covered Recipient Entity
TMC HEALTHCARE
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385834
Principal investigator 1 Exelixis Inc. $6,251.15 07/17/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379604
Principal investigator 1 Exelixis Inc. $5,080.70 06/11/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379602
Principal investigator 1 Exelixis Inc. $2,311.15 05/13/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379600
Principal investigator 1 Exelixis Inc. $7,782.85 04/11/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379598
Principal investigator 1 Exelixis Inc. $935.00 03/19/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379592
Principal investigator 1 Exelixis Inc. $19,053.50 02/27/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379596
Principal investigator 1 Exelixis Inc. $1,870.00 01/17/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY ASSOCIATES
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379594